Pfizer and BioNTech have launched a clinical trial to study the effectiveness of an Omicron-specific COVID-19 vaccine, the companies announced Tuesday.The drugmakers said the study will evaluate the safety and immune response of the new inoculation in up to 1,420 healthy adults ages 18 through 55.The first group of participants, some 615 people, have received two doses of the current Pfizer-BioNTech vaccine between 90 and 180 days of enrolling in the study. They’ll then receive one or two doses of the Omicron-targeted shot.
Load More
Load More